VBL Therapeutics (VBLT) Stock: Flying On Data Presentation

VBL Therapeutics (NASDAQ: VBLT) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company presented data with regard to its novel MOSPD2 program in oncology and inflammation, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The data; what we’re seeing from the … Read more

VBL Therapeutics (VBLT) Stock: Gaining On Positive Trial News

VBL Therapeutics (NASDAQ:VBLT) is having an incredibly strong time in the pre-market hours this morning, and for good reason. The company got great news from the Independent Data Safety Monitoring Committee surrounding one of its trials. As a result, investors got excited, pushing the stock upward. Of course, our partners at Trade Ideas were the … Read more

Vascular Biogenics (VBLT) Stock: Gaining Big On Phase 2 Data

Vascular Biogenics Ltd (NASDAQ: VBLT) Vascular Biogenics is having a great start to the trading session today, and for good reason. The company released overwhelmingly positive results from a recent Phase II clinical study. As a result, the stock started to climb dramatically, causing our partners at Trade Ideas to alert us of the gains. … Read more

Morning Buzz: Prana Biotechnology (PRAN), Heron Therapeutics (HRTX), Vascular Biogenics (VBLT), Clovis Oncology (CLVS)

Prana Biotechnology Limited (PRAN) shares surged 19.26% to $1.61 in early trading following the company’s announcement that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington’s disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington’s disease. Shares of Heron Therapeutics, Inc. (HRTX) … Read more